Biotech News

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Disc Medicine (IRON)Disc Medicine2026-06-25 13:46 ESTClinical readout

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc.

Open original release

Related news

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

IRONDisc Medicine2026-06-25 13:46 EST

Disc Medicine to Participate in Upcoming Investor Conferences

View all latest news

Disc Medicine

Disc Medicine is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

IRONZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

IRONZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

IRONBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

IRONGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

IRONMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 75.98 USD
Market cap: 2.93B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States